Clinical evaluation of radiotherapy for no hypopharyngeal cancer

Yoshiyuki Shioyama, Katsumasa Nakamura, Tomonari Sasaki, Saiji Ohoga, Madoka Saku, Yusuke Urashima, Tadamasa Yoshitake, Hiroshi Honda, Yuichirou Kuratomi, Torahiko Nakashima, Shizuo Komune, Kenichi Jingu, Hiromi Terashima

Research output: Contribution to journalArticle

Abstract

Seventy-five hypopharyngeal cancer patients without lymph-node metastasis, treated with radiotherapy at Kyushu University Hospital from 1976 through 2003, were evaluated. T category was 10 in T1, 41 in T2, 13 in T3, and 11 in T4. Median total doses of radiation therapy were 62.5Gy (range : 60-74Gy) in radical intent, and 30Gy (28.5-41.4Gy) in the preoperative setting. Patient selection as to radical radiotherapy or preoperative irradiation plus surgery was performed at 30-40Gy by an oncologist of head and neck surgery and a radiation oncologist, according to the tumor response to radiation therapy. Most patients were treated with radiotherapy combined with concurrent chemotherapy including 5-fluorouracil (5-FU) and Vitamin A. As the result, radical radiotherapy was selected for 48 patients (T1, 9; T2, 30; T3, 4; T4, 5), and preoperative irradiation plus surgery was selected for 27 patients (T1, 1; T2, 11; T3, 9; T4, 6) For 75 T1-4 cancer patients, the 5-year overall and cause-specific survival rates were 62% and 75%, respectively. The 5-year cause-specific survival (5y-CSS) rates were 100% for T1, 85% for T2, 83% for T3, and 30% for T4. For patients with T1-2 cancers, there was no significant difference in survival between the RT+Surgery group and the RT group; 5-year CSS was 92% vs. 85%, respectively. In the RT group, however, the prognosis of patients with T3-4 cancers (5-year CSS : 29%) was significantly poor compared with that of patients with T1-2 cancers. The 5-year local progression-free survival with laryngeal preservation was 65% in T1-2 cancers, 6% in T3-4 cancers, and 45% in all patients. Radiotherapy has an advantage for the preservation of laryngeal function compared with surgery. For stage I-II cancers, therefore, radiotherapy should be first considered as a radical treatment option. For T3-4 cancers, however, the combination of radiotherapy and surgery was thought to be proper treatment.

Original languageEnglish
Pages (from-to)563-569
Number of pages7
JournalToukeibu Gan
Volume30
Issue number4
DOIs
Publication statusPublished - Jan 1 2004

    Fingerprint

All Science Journal Classification (ASJC) codes

  • Otorhinolaryngology
  • Oncology

Cite this

Shioyama, Y., Nakamura, K., Sasaki, T., Ohoga, S., Saku, M., Urashima, Y., ... Terashima, H. (2004). Clinical evaluation of radiotherapy for no hypopharyngeal cancer. Toukeibu Gan, 30(4), 563-569. https://doi.org/10.5981/jjhnc.30.563